Omeros/$OMER
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Omeros
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
- Ticker
- $OMER
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 175
- Headquarters
- Seattle, United States
- Website
- www.omeros.com
Omeros Metrics
BasicAdvanced
$1.3B
11.74
$1.57
2.60
-
Price and volume
Market cap
$1.3B
Beta
2.6
52-week high
$21.24
52-week low
$6.24
Average daily volume
1.2M
Financial strength
Current ratio
1.951
Quick ratio
1.614
Long term debt to equity
-4.626
Total debt to equity
-5.781
Interest coverage (TTM)
-3.25%
Profitability
EBITDA (TTM)
-71.913
Gross margin (TTM)
-18.14%
Net profit margin (TTM)
324.88%
Operating margin (TTM)
-189.53%
Effective tax rate (TTM)
1.77%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-18.68%
Return on equity (TTM)
-83.23%
Valuation
Price to earnings (TTM)
11.736
Price to revenue (TTM)
33.769
Price to book
-25.9
Price to tangible book (TTM)
-25.9
Price to free cash flow (TTM)
7.575
Free cash flow yield (TTM)
13.20%
Free cash flow per share (TTM)
2.434
Growth
Earnings per share change (TTM)
-174.52%
10-year revenue growth (CAGR)
3.45%
3-year earnings per share growth (CAGR)
34.79%
10-year earnings per share growth (CAGR)
-1.89%
What the Analysts think about Omeros
Analyst ratings (Buy, Hold, Sell) for Omeros stock.
Analyst projections of the future price of Omeros stock.
Bulls say / Bears say
YARTEMLEA generated $28.5 million in net sales in the second quarter, its first full commercial quarter, giving Omeros a growing revenue base after FDA approval for TA-TMA. (Omeros)
Omeros reduced the principal on its 2029 convertible notes by 43% in July, cut potential conversion shares and removed $8.6 million in future interest payments. That eases future financing costs and potential dilution. (Omeros)
The EMA confirmed its refusal of YARTEMLEA after re-examination, concluding that the benefits and risks were not established. This blocks the expected EU route to market unless the company can resolve regulators’ evidence concerns. (European Medicines Agency)
Omeros’s current commercial franchise centres on one drug for TA-TMA, while its other MASP-2 candidate has completed only Phase 1 and further studies are still being planned. That leaves limited near-term product diversification if YARTEMLEA’s uptake disappoints. (Omeros)
The reported $132 million in cash and short-term investments was measured before Omeros spent $60.2 million on July note repurchases; $40.3 million of note principal remained, and operating cash use totalled $10.4 million in the first half. This leaves less room to fund commercial growth and development if cash generation weakens. (Omeros, SEC)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
Omeros Financial Performance
Revenues and expenses
Omeros Earnings Performance
Company profitability
Upcoming events
No upcoming events
Omeros News
AllArticlesVideos
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
Benzinga2 weeks ago
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
Business Wire2 weeks ago
Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst
Benzinga1 month ago
Funds containing Omeros
Fund name | Fund size | $OMER weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.09% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.09% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.